HIPEC Surgery for Peritoneal Mesothelioma: What Patients Need to Know

HIPEC surgery for peritoneal mesothelioma is a combined treatment approach that pairs a long abdominal operation with a heated chemotherapy bath delivered directly inside the belly. It is most often discussed under the longer name cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy, often shortened to CRS plus HIPEC. The procedure is considered for select patients whose mesothelioma is confined to the lining of the abdomen, and it has become one of the most studied treatment options for this rare cancer [1][2].

This article is part of the mesothelioma treatment options overview on Mesothelioma Cancer Help. Below you will find a plain-language explanation of what HIPEC is, why it is used for peritoneal disease specifically, how the procedure unfolds, what recovery generally looks like, and what published medical sources say about outcomes and risks. The goal is to help patients and families understand the procedure well enough to have a meaningful conversation with a qualified oncology team.

Key takeaways

• HIPEC, short for hyperthermic intraperitoneal chemotherapy, is heated chemotherapy circulated inside the abdomen at roughly 41 to 43 degrees Celsius (about 105 to 109 degrees Fahrenheit) for 60 to 120 minutes after surgery removes visible tumor [3][4].
• HIPEC is paired with cytoreductive surgery (CRS) as a single 8 to 12 hour operation, performed at high-volume cancer centers for carefully selected patients with peritoneal mesothelioma [2][4].
• Published case series report median overall survival of about 30 to 90 months for selected patients undergoing CRS plus HIPEC, versus roughly 12 months on chemotherapy alone [6].
• Major complications are reported in roughly 30 to 50 percent of cases, with procedure-related mortality typically in the low single digits at experienced centers [6].
• CRS plus HIPEC is not considered universally curative and is one option alongside systemic chemotherapy, immunotherapy, clinical trials, and supportive care [1][6].

What HIPEC is

HIPEC stands for hyperthermic intraperitoneal chemotherapy: a one-time delivery of warmed chemotherapy directly into the abdominal cavity at the end of a surgery that has already removed as much visible cancer as possible [3]. The chemotherapy solution is circulated through the abdomen for roughly 60 to 120 minutes at a temperature near 41 to 43 degrees Celsius (about 105 to 109 degrees Fahrenheit), then drained out before the surgical team closes the incision [4].

The peritoneum is the thin membrane that lines the inside of the abdominal wall and covers most abdominal organs. Peritoneal mesothelioma is a cancer that arises in this lining, most often after long-ago asbestos exposure. Because the disease typically spreads across the surface of the peritoneum rather than forming a single isolated tumor, treatments that can blanket the entire abdominal surface have a biologic rationale that traditional intravenous chemotherapy does not match in the same way [5].

How HIPEC differs from standard intravenous chemotherapy

Intraperitoneal chemotherapy bathes only the abdominal cavity, which allows much higher local drug concentrations with less whole-body toxicity than chemotherapy delivered through a vein [3][6]. Standard chemotherapy travels everywhere in the body via the bloodstream. That systemic exposure is useful for cancers that may have already spread, but it also means the dose has to be limited because the drugs affect healthy tissue throughout the body. The added heat in HIPEC is thought to improve drug penetration into the peritoneal surface and to have direct cytotoxic effects on cancer cells, although the relative contribution of heat versus the chemotherapy drug itself remains an active research question [6].

Why HIPEC is used for peritoneal mesothelioma

Peritoneal mesothelioma is rare, with roughly 250 to 500 cases diagnosed each year in the United States, and published clinical reviews describe CRS plus HIPEC as the most widely studied therapy for this disease [6][7]. Several large case series report median overall survival in the range of 30 to 90 months for carefully selected patients, compared with historical reports of roughly 12 months on chemotherapy alone [6]. Because the disease tends to remain inside the abdomen for much of its course, local treatments that target the peritoneal surface can be especially relevant. These figures are aggregate statistics, not predictions for any individual person, and outcomes vary widely based on disease extent, histologic subtype, and how completely the surgery can remove visible cancer.

It is also important to be clear about what HIPEC is not. The combined CRS plus HIPEC approach is not considered universally curative, and many medical centers describe it as a way to extend life and reduce disease burden rather than a way to eliminate mesothelioma entirely [1][6]. It is one option within a broader treatment landscape that may also include systemic chemotherapy, immunotherapy, clinical trials, and supportive care.

How cytoreductive surgery and HIPEC work together

CRS plus HIPEC is planned as a single operation with two linked goals: cytoreductive surgery removes all visible tumor from the peritoneal cavity, and HIPEC then delivers heated chemotherapy to treat the microscopic disease that remains. Patient resources from major cancer centers and a peer-reviewed review in the National Library of Medicine all describe HIPEC as most effective when paired with thorough cytoreductive surgery first [2][6].

The cytoreductive surgery phase

Cytoreductive surgery, sometimes called CRS or debulking, is the part of the operation in which the surgical team works through the abdomen to remove all visible tumor implants from the peritoneum and from any affected organs [2]. Depending on where the disease has spread, this can include removing portions of the omentum (the fatty apron that hangs from the stomach), parts of the bowel, the spleen, the gallbladder, the peritoneal lining itself, and other involved tissues. The surgeon assigns a Peritoneal Cancer Index, or PCI, that scores how widely the cancer is distributed across 13 abdominal regions, and a completeness of cytoreduction score, often called CC score, that describes how much residual disease remains after the resection [6].

Survival outcomes in published case series are strongly associated with achieving a complete or near-complete cytoreduction, sometimes called CC-0 or CC-1 status, meaning either no visible residual tumor or only nodules smaller than a defined threshold [6].

The heated chemotherapy phase

Once cytoreduction is complete, the surgical team places inflow and outflow catheters in the abdomen and connects them to a perfusion machine. The machine circulates a chemotherapy solution, most commonly cisplatin for peritoneal mesothelioma, sometimes combined with another agent such as doxorubicin or mitomycin C, through the heated abdomen for the prescribed time [3][6]. The drug combination, temperature, and duration are chosen by the surgical and oncology team based on the patient situation and institutional protocols. After the perfusion period ends, the solution is drained, the abdomen is rinsed, the catheters are removed, and the incision is closed [4].

What the procedure timeline typically looks like

The combined CRS plus HIPEC operation usually runs 8 to 12 hours under general anesthesia, with the cytoreductive portion accounting for most of that time and the HIPEC perfusion adding about 1 to 2 hours [2][4]. It is one of the longer procedures performed in oncologic surgery.

Most patients then spend at least one night in an intensive care unit for close monitoring of fluids, pain control, and organ function. Total hospital stays typically run from about 7 to 14 days, depending on how the patient recovers and whether any complications arise [4][6]. Return to baseline activity, with energy and weight stabilized, often takes 2 to 3 months or longer.

Who doctors generally consider for the procedure

Patient selection is one of the most consequential parts of the entire treatment plan. Published reviews and major cancer center criteria describe a set of factors that surgical teams typically weigh together, rather than any single threshold [2][6]:

• Confirmed diagnosis of peritoneal mesothelioma, most often the epithelioid subtype, which generally has better outcomes than biphasic or sarcomatoid subtypes
• Disease that remains confined to the peritoneal cavity, without distant spread to lymph nodes outside the abdomen, the lungs, or other organs
• A Peritoneal Cancer Index considered low enough that complete or near-complete cytoreduction is realistic
• Overall physical condition, often described as performance status, sufficient to tolerate a long operation and a substantial recovery
• Acceptable function of the heart, kidneys, lungs, and liver based on preoperative testing
• Absence of medical conditions that would make the chemotherapy drugs particularly hazardous

These are general considerations described in the medical literature, not personal recommendations. Whether HIPEC is appropriate for a specific individual is a medical decision made by an experienced peritoneal surface malignancy team after a complete workup.

Recovery, hospital stay, and follow-up

Total hospital stays after CRS plus HIPEC typically run 7 to 14 days, beginning with at least one night in an intensive care unit, and return to baseline activity often takes 2 to 3 months or longer [4][6]. Common elements of the recovery period include:

• An initial intensive care stay focused on circulatory stability and pain control
• A nasogastric tube and intravenous nutrition for some days while bowel function returns
• Gradual reintroduction of clear liquids, then a regular diet, over the first week
• Drains placed during surgery that are removed as output decreases
• Wound care education before discharge
• Outpatient follow-up visits beginning a few weeks after surgery
• Imaging surveillance, typically with CT scans, every few months for several years

Some patients also receive systemic chemotherapy or other treatments before or after the operation, depending on the care team plan [1]. Long-term follow-up is generally lifelong, since peritoneal mesothelioma can recur even after a complete cytoreduction.

Potential risks and side effects

CRS plus HIPEC is a high-intensity procedure, and published case series report major complications in roughly 30 to 50 percent of cases, with procedure-related mortality typically in the low single digits at experienced centers [6]. Reported risks include [4][6]:

• Bleeding requiring transfusion or reoperation
• Infection, including wound infection and intra-abdominal abscess
• Anastomotic leak, meaning leakage where two segments of bowel have been rejoined
• Bowel obstruction or prolonged ileus, meaning slow return of bowel function
• Blood clots in the legs or lungs
• Kidney injury, often related to the chemotherapy drugs and fluid shifts during surgery
• Bone marrow suppression with low blood counts in the weeks after surgery
• Hearing changes and neuropathy associated with cisplatin
• Pulmonary complications such as pneumonia

The literature consistently notes that outcomes are best at high-volume centers with dedicated peritoneal surface malignancy programs and that complication rates are lower when such centers manage the entire pathway [2][6]. Patients and families considering HIPEC are generally encouraged to ask any prospective program how many CRS plus HIPEC procedures it performs each year and what its institution-specific outcomes look like.

Questions patients commonly ask their care team

Beyond the technical details of the procedure, patients and families often want to talk through how the operation fits into their personal situation. Examples of questions that an oncology team can answer in context include:

• How extensive does the team expect the disease to be based on imaging and biopsy results, and what is the estimated Peritoneal Cancer Index?
• What is the goal of surgery in this case, complete cytoreduction or maximal debulking?
• Which chemotherapy agent or combination does the program use, and why?
• What are the program outcomes for patients with a similar disease pattern?
• What is the expected length of hospital stay and the timeline for returning to activities?
• What follow-up imaging and visits are planned after surgery?
• What clinical trials, if any, are open at this center for peritoneal mesothelioma?

A second opinion from another mesothelioma program is also a common step before committing to a procedure of this magnitude.

FAQ

What is the survival rate after HIPEC surgery for peritoneal mesothelioma?

Published case series report median overall survival ranging from about 30 to 90 months for patients selected for CRS plus HIPEC, compared with historical figures near 12 months on chemotherapy alone [6]. Outcomes depend on histologic subtype, disease extent, and completeness of surgery, and these aggregate figures are not predictions for any individual situation.

How long does HIPEC surgery take?

The full operation usually runs 8 to 12 hours under general anesthesia. The cytoreductive surgery phase, removing visible tumor and affected tissues, takes the majority of that time. The HIPEC perfusion phase itself, when heated chemotherapy is circulated in the abdomen, generally lasts about 60 to 120 minutes inside that broader window [2][4].

What is the recovery time for HIPEC and cytoreductive surgery?

Most patients spend roughly 7 to 14 days in the hospital, often starting with a night or more in an intensive care unit. Return to baseline energy, weight, and activity often takes 2 to 3 months and sometimes longer. Outpatient follow-up and imaging surveillance continue for years, since peritoneal mesothelioma can recur after surgery [4][6].

Who is a candidate for HIPEC surgery?

Care teams generally consider patients with confirmed peritoneal mesothelioma, often the epithelioid subtype, whose disease appears confined to the abdomen and whose overall health, organ function, and disease extent suggest that a complete or near-complete cytoreduction is achievable [2][6]. Whether HIPEC is appropriate for a specific person is a medical decision made after a full workup.

What are the side effects of HIPEC chemotherapy?

The heated chemotherapy is typically cisplatin, sometimes combined with another agent. Reported side effects include kidney injury, bone marrow suppression with low blood counts, nausea, hearing changes, neuropathy, and electrolyte disturbances [6]. Most reactions occur in the weeks after surgery and are managed in coordination with the medical oncology team alongside surgical recovery.

Is HIPEC covered by insurance?

Coverage varies by insurer, plan, and indication. Major United States cancer centers generally treat CRS plus HIPEC for peritoneal mesothelioma as an accepted, evidence-supported procedure, and many private insurers and Medicare provide coverage when criteria are met. Patients can ask the cancer center financial services team for a benefits review before scheduling, since prior authorization is common.

Conclusion

For carefully selected patients with peritoneal mesothelioma, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is one of the most studied treatment options and has been associated with longer reported survival in published case series than chemotherapy alone. It is also a long, demanding operation with meaningful risks and a significant recovery period, and it is not appropriate for every patient. The decision to pursue HIPEC is best made with an experienced peritoneal surface malignancy team that can evaluate disease extent, histology, overall health, and individual priorities. Reliable information from federal cancer agencies, major cancer centers, and peer-reviewed reviews can help patients and families ask informed questions throughout that process.

Sources

1. National Cancer Institute. Malignant Mesothelioma Treatment (PDQ), Patient Version. https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq
2. Memorial Sloan Kettering Cancer Center. HIPEC for Peritoneal Mesothelioma. https://www.mskcc.org/cancer-care/types/mesothelioma-peritoneal/treatment/hipec
3. Cleveland Clinic. HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Procedure and Recovery. https://my.clevelandclinic.org/health/treatments/hipec-hyperthermic-intraperitoneal-chemotherapy
4. Moffitt Cancer Center. HIPEC Treatment. https://www.moffitt.org/treatments/hipec/
5. American Cancer Society. Surgery for Malignant Mesothelioma. https://www.cancer.org/cancer/types/malignant-mesothelioma/treating/surgery.html
6. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-Analysis. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/25193017/
7. National Cancer Institute. About Mesothelioma. https://www.cancer.gov/types/mesothelioma

Last reviewed: 2026-05-22

Mesothelioma Cancer Help is an independent information resource. We are not a law firm, medical provider, or patient services organization, and we do not provide legal, medical, or financial advice. Information on this site is for general educational purposes only. Always consult a qualified medical professional for questions about your health, and a licensed attorney for questions about your legal rights. If you are in a medical emergency, call 911 or go to your nearest emergency room.